Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Hypomethylating agents (HMAs) in combination with venetoclax have been widely adopted as the standard of care for patients who cannot tolerate induction chemotherapy and for patients who have relapsed/refractory (R/R) acute myeloid leukemia (AML). This study retrospectively analyzed the outcomes of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hemasphere
Main Authors: Feld, Jonathan, Tremblay, Douglas, Dougherty, Mikaela, Czaplinska, Tina, Sanchez, Gillian, Brady, Claudia, Kremyanskaya, Marina, Bar-Natan, Michal, Keyzner, Alla, Marcellino, Bridget K., Gabrilove, Janice, Navada, Shyamala C., Silverman, Lewis R., El Jamal, Siraj M., Mascarenhas, John, Shih, Alan H.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7951133/
https://ncbi.nlm.nih.gov/pubmed/33718803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000549
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados